IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 2557 
Small font sizeDefault font sizeIncrease font size
Read this article


    Article Cited by others


Biosimilars: Current perspectives and future implications

Misra Monika

Year : 2012| Volume: 44| Issue : 1 | Page no: 12-14

   This article has been cited by
1 Methodology for constructing scenarios for health policy research: The case of coverage decision-making for drugs for rare diseases in Canada
Conor M.W. Douglas, Dimitra Panagiotoglou, Nick Dragojlovic, Larry Lynd
Technological Forecasting and Social Change. 2021; 171: 120960
[Pubmed]  [Google Scholar] [DOI]
2 A comparative study between ranibizumab and its first biosimilar razumab in terms of efficacy and safety in DME, RVO and wet AMD associated with CNVM
Preethi B, Shilpa G, Dhwani Anil Shah, Praveen R Murthy
Indian Journal of Clinical and Experimental Ophthalmology. 2021; 7(2): 346
[Pubmed]  [Google Scholar] [DOI]
Ria Christine Siagian, Novilia Bachtiar, Prastuti Soewondo
INDIAN DRUGS. 2021; 58(06): 07
[Pubmed]  [Google Scholar] [DOI]
4 Similar biologics in India: A story of access or potential for compromise?
Ramesh Jois, Sukumar Mukherjee, S Rajeswari, PD Rath, Vishal Goyal, Disha Gupta
Indian Journal of Medical Research. 2020; 152(5): 456
[Pubmed]  [Google Scholar] [DOI]
5 Biosimilars: Challenges and path forward
Young Sik Kim,Byung Wook Choi,Sung Wook Yang,Seon Mi Shin,Sang Wook Nam,Yun Sook Roh,Jae Young Lee,Kyung Jin Lee,Yong Jick Kim,Jun-Young Kwon,Dong-Il Kim
Biotechnology and Bioprocess Engineering. 2014; 19(5): 755
[Pubmed]  [Google Scholar] [DOI]
6 Drug Discovery Research in India: Current State and Future Prospects
Tanjore Balganesh, Tapas K. Kundu, Tushar Kanti Chakraborty, Siddhartha Roy
ACS Medicinal Chemistry Letters. 2014; 5(7): 724
[Pubmed]  [Google Scholar] [DOI]
7 Biosimilars in Oncology: From Development to Clinical Practice
Katherine H. Rak Tkaczuk,Ira Allen Jacobs
Seminars in Oncology. 2014; 41: S3
[Pubmed]  [Google Scholar] [DOI]
8 Biosimilar Insulins Are Coming: What They Are, What You Need To Know
Steven Edelman,William H. Polonsky,Christopher G. Parkin
Current Medical Research and Opinion. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]
9 Comparison of global regulatory approvals for Biosimilar products
Konangi, S., Raviteja, M.N., Vishal Gupta, N.
International Journal of PharmTech Research. 2013; 5(3): 924-935
[Pubmed]  [Google Scholar]
10 Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics
Devlin, S.M., Bressler, B., Bernstein, C.N., Singh, H., Feagan, B.G.
Canadian Journal of Gastroenterology. 2013; 27(10): 567-271
[Pubmed]  [Google Scholar]
11 Biosimilars in IBD: Hope or expectation?
Gecse, K.B., Khanna, R., Van Den Brink, G.R., Feagan, B.G., DæHaens, G.R.A.M.
Gut. 2013; 62(6): 803-807
[Pubmed]  [Google Scholar]
12 Special characteristics and risk management of biologicals and biosimilars
Shi, S., Chen, D.
Pharmaceutical Care and Research. 2012; 12(5): 326-329+386
[Pubmed]  [Google Scholar]
13 Biosimilar DMARD in rheumatology: A general perspective with focus on India
Arvind Chopra,Subramanian Shankar
Indian Journal of Rheumatology. 2012; 7(2): 89
[Pubmed]  [Google Scholar] [DOI]
14 Biosimilars in rheumatology; the new kid in the block: Panacea or pandoras box?
Krishnan Shanmuganandan,Darshan S. Bhakuni
Indian Journal of Rheumatology. 2012; 7(2): 67
[Pubmed]  [Google Scholar] [DOI]


Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow